EP Patent

EP4706651A2 — New formulations and uses

Assigned to Alzecure Pharma AB · Expires 2026-03-11 · 0y expired

What this patent protects

There is provided a pharmaceutical composition comprising the compound N-[(1S)-1-(4-tert-butylphenyl)ethyl]-2-(6,7-difluoro-1H-benzimidazol-1-yl)acetamide, or pharmaceutically acceptable salt thereof, for use in the treatment of pain by topical administration of the composition t…

USPTO Abstract

There is provided a pharmaceutical composition comprising the compound N-[(1S)-1-(4-tert-butylphenyl)ethyl]-2-(6,7-difluoro-1H-benzimidazol-1-yl)acetamide, or pharmaceutically acceptable salt thereof, for use in the treatment of pain by topical administration of the composition to a body surface.

Drugs covered by this patent

Patent Metadata

Patent number
EP4706651A2
Jurisdiction
EP
Classification
—
Expires
2026-03-11
Drug substance claim
No
Drug product claim
No
Assignee
Alzecure Pharma AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.